论文部分内容阅读
作者用双盲对照法评价吸附剂(Sorbent,AST-120)治疗尿毒症的疗效。将病人随机分为AST-120组(27例)和对照组(24例)。AST-120组病人开始透析之前2.4～30.1(平均13.2±7.4)月,每日服AST 3.2～7.2g,对照组病人开始透析前4.2～12.6(平均10.5±2.5)月接受常规治疗。定期测定血清肌酐、尿素氮、总蛋白和磷浓度以及红细胞数,如病人出现尿毒症症状和血清肌酐达10mg/dl开始透析治疗。结果,倒数肌酐V时间斜率,对照组开始透析前的6～12月为每月-1251±856×
The authors evaluated the efficacy of sorbent (AST-120) in the treatment of uremia by double-blind comparison. Patients were randomly divided into AST-120 group (27 cases) and control group (24 cases). Patients in the AST-120 group had a daily AST of 3.2 to 7.2 g before dialysis between 2.4 and 30.1 months (mean, 13.2 ± 7.4) months and 4.2 to 12.6 (mean, 10.5 ± 2.5) months before starting dialysis in the control group. Regular serum creatinine, urea nitrogen, total protein and phosphorus concentrations and the number of red blood cells, such as uremia symptoms and serum creatinine patients up to 10mg / dl dialysis treatment. As a result, the slope of the reciprocal creatinine V time was 6-12 months before dialysis in the control group to -1251 ± 856 ×